Boshuizen, Julia http://orcid.org/0000-0002-8135-0525
Vredevoogd, David W. http://orcid.org/0000-0001-6718-1422
Krijgsman, Oscar
Ligtenberg, Maarten A.
Blankenstein, Stephanie
de Bruijn, Beaunelle
Frederick, Dennie T.
Kenski, Juliana C. N.
Parren, Mara http://orcid.org/0000-0003-0067-0154
Brüggemann, Marieke
Madu, Max F.
Rozeman, Elisa A.
Song, Ji-Ying
Horlings, Hugo M. http://orcid.org/0000-0003-4782-8828
Blank, Christian U. http://orcid.org/0000-0002-7945-5846
van Akkooi, Alexander C. J.
Flaherty, Keith T. http://orcid.org/0000-0002-3402-0478
Boland, Genevieve M. http://orcid.org/0000-0002-7522-6173
Peeper, Daniel S. http://orcid.org/0000-0003-1293-3177
Article History
Received: 19 November 2019
Accepted: 10 July 2020
First Online: 7 August 2020
Competing interests
: The authors declare the following competing interests: C.U.B. receives grants and/or research support from Novartis, BMS, and NanoString, and has received honoraria or consultation fees for MSD, BMS, Roche, Novartis, GSK, Pfizer, Lilly, Genmab, and Pierre Fabre. C.U.B. and D.S.P. are co-founders, shareholders and advisors of Immagene B.V. M.A.L. is co-founder, shareholder and CEO of Immagene B.V., unrelated to this study. K.T.F. has served on the Board of Directors of Clovis Oncology, Strata Oncology, Loxo Oncology, and Checkmate Pharmaceuticals; Scientific Advisory Boards of X4 Pharmaceuticals, PIC Therapeutics, Sanofi, Amgen, Asana, Adaptimmune, Fount, Aeglea, Shattuck Labs, Tolero, Apricity, Oncoceutics, Fog Pharma, Neon, Tvardi, xCures, Monopteros, and Vibliome; consultant to Lilly, Novartis, Genentech, BMS, Merck, Takeda, Verastem, Boston Biomedical, Pierre Fabre, and Debiopharm; and research funding from Novartis and Sanofi. G.M.B. has sponsored research agreements with Olink Pharmaceuticals, Palleon Pharmaceuticals, and Takeda Oncology. She has been on scientific advisory boards for Nectar Therapeutics and Novartis and served as a speaker for Novartis. All the other authors declare no competing interests.